Previous 10 | Next 10 |
CHICAGO and BURLINGTON, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- The National Basketball Retired Players Association (NBRPA) and Flexion Therapeutics Inc. today announced a new partnership to raise awareness of osteoarthritis-related knee pain and present ZILRETTA (triamcinolone acetonide e...
Flexion Therapeutics recently reported their Q4 and full-year 2020 results that revealed record sales for ZILRETTA and encouraging commercial metrics. Despite the COVID-19 headwinds, the company continues to report growth and commercial prowess. I believe ZILRETTA's extended release p...
Flexion Therapeutics ([[FLXN]] -2.5%) has issued guidance for Q4 2020 and sees Zilretta sales of ~26.3M, slightly higher than consensus estimate of $25.7. For FY2020, expects net sales of ~$85.5M."As a result of specialty distributor purchases in response to growing customer demand ...
Fourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 million Full-year 2020 net sales estimated to be approximately $85.5 million Company names Adam Muzikant, Ph...
BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference. The virtual fi...
BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeuti...
Miller Value Partners is a value investor. It values businesses, and not just stocks, and invests in them for the long term. During the third quarter of 2020, Miller Opportunity Equity returned 13.01% (net of fees) versus the unmanaged benchmark, the S&P 500 Index, return of 8.93%...
BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29 th Annual Credit Suisse Virtual Healthcare Conferen...
Flexion Therapeutics (FLXN): Q3 GAAP EPS of -$0.50 beats by $0.01.Revenue of $23.66M (+8.6% Y/Y) beats by $0.04M.Press Release For further details see: Flexion Therapeutics EPS beats by $0.01, beats on revenue
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial res...
News, Short Squeeze, Breakout and More Instantly...
Flexion Therapeutics Inc. Company Name:
FLXN Stock Symbol:
NASDAQ Market:
Flexion Therapeutics Inc. Website:
-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc...